SCHEMBL2993407

SCHEMBL2993407

CC(=O)c1cn(S(=O)(=O)c2ccccc2)c2nccc(OC(C)C)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP2C19 P33261 2/20 0.38
PLK1 P53350 1/20 0.37
HTR6 P50406 4/20 0.36
PKM P14618 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
PTGDR Q13258 1/20 0.35
PTGDR2 Q9Y5Y4 2/20 0.34
DRD2 P14416 2/20 0.34
MAPT P10636 1/20 0.34
GSK3A P49840 1/20 0.34
IRAK4 Q9NWZ3 1/20 0.34
KAT6A Q92794 2/20 0.34
MET P08581 1/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C1 Q04828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999849 0.89 LMNA (0.49) LMNASMN1; SMN2MEN1KMT2ACYP2C19
SCHEMBL2986139 0.87 LMNA (0.47) LMNASMN1; SMN2MEN1KMT2ACYP2C19
SCHEMBL2995312 0.85 SMN1; SMN2 (0.46) LMNASMN1; SMN2MEN1KMT2ACYP2C19
SCHEMBL2994911 0.85 LMNA (0.46) LMNASMN1; SMN2MEN1KMT2ACYP2C19
SCHEMBL2993714 0.84 BRD4 (0.41) LMNASMN1; SMN2MEN1KMT2ACYP2C19
SCHEMBL2237471 0.81 LMNA (0.51) LMNASMN1; SMN2MEN1KMT2ACYP2C19
SCHEMBL30093744 0.81 LMNA (0.42) LMNASMN1; SMN2MEN1KMT2ACYP2C19
SCHEMBL2997418 0.81 LMNA (0.42) LMNASMN1; SMN2MEN1KMT2ACYP2C19
SCHEMBL2995288 0.81 LMNA (0.50) LMNASMN1; SMN2MEN1KMT2ACYP2C19
SCHEMBL2994359 0.80 LMNA (0.41) LMNASMN1; SMN2HTR6IRAK4KAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184790-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184790-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF BAD, PPOX, CASP3 LMNA 4217/4885SMN1; SMN2 954/4885MEN1 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.